CIPLA PACLITAXEL Paclitaxel (nanoparticle albumin-bound) 100 mg powder for injection (suspension) vial

Land: Australien

Sprog: engelsk

Kilde: Department of Health (Therapeutic Goods Administration)

Aktiv bestanddel:

paclitaxel, Quantity: 100 mg

Tilgængelig fra:

Cipla Australia Pty Ltd

Lægemiddelform:

Injection, powder for

Sammensætning:

Excipient Ingredients: Albumin; N-acetyl-dl-tryptophan; sodium octanoate

Indgivelsesvej:

Intravenous

Enheder i pakken:

1 x 50 mL vial

Recept type:

(S4) Prescription Only Medicine

Terapeutiske indikationer:

Metastatic breast cancer: Cipla Paclitaxel is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. Non-small Cell Lung Cancer: Cipla Paclitaxel, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation. Metastatic Adenocarcinoma of the Pancreas: Cipla Paclitaxel, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.

Produkt oversigt:

Visual Identification: Nano-paclitaxel injection is a sterile white to yellow lyophilized cake or powder in a 50 mL USP Type I flint glass vial.; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Autorisation status:

Registered

Autorisation dato:

2020-10-29